

Ref: FOI/GS/ID 9338

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

22 August 2024

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to acute myeloid leukaemia (AML).

You asked: All questions are shown as received by the Trust.

1. Please complete the table below with how many newly diagnosed patients with AML have started first-line treatment with each of the following therapies during the 6-month period February 2024 to July 2024?

- *Azacitidine monotherapy*
- *Low dose cytarabine (LoDAC) monotherapy*
- *Venetoclax + azacitidine*
- *Venetoclax + LoDAC*
- *Ivosidenib*
- *Intensive chemotherapy-based regimen*

O Examples include: cytarabine and daunorubicin, idarubicin, fludarabine, mitoxantrone, etoposide (VP-16), 6-thioguanine (6-TG), methotrexate (MTX) or 6-mercaptopurine (6-MP), gemtuzumab ozogamicin with daunorubicin cytarabine, or FLAG-Ida (fludarabine, cytarabine, granulocyte-colony stimulating factor and idarubicin)

- *Best supportive care*
- *Other*

O Do not include prophylactic therapies such as GCSF, anti-fungals, antihistamines, anti-nauseants

Trust response:

Treatment option	Number of newly diagnosed patients with AML starting first line treatment during the 6-month period February 2024 to July 2024
Azacitidine monotherapy	1
LoDAC monotherapy	0
Venetoclax + azacitidine	6
Venetoclax + LoDAC	0
Ivosidenib	0
Intensive chemotherapy-based regimen	5
Best supportive care	0
Other	0